NetworkNewsBreaks – Lexaria Bioscience Corp. (NA
Post# of 420
(Total Views: 199)
Posted On: 12/20/2022 4:16:01 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Dosing in Its Human Oral Nicotine Study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing has begun in its human clinical nicotine study NIC-H22-1. Current cigarette smokers are participating in the 36-person human pharmacokinetic randomized, double blinded, cross-over study, wherein each person will visit the laboratory to be dosed three times over the coming weeks. Only one oral nicotine pouch (DehydraTECH-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match) will be administered and evaluated during each visit. The primary objectives are to determine the quantity of nicotine in blood at various time points and collection of vital-sign data of temperature, blood pressure, heart rate and respiratory rate. In addition, subjective evaluations related to throat burn, user experience, gastrointestinal experience and more will be conducted.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that dosing has begun in its human clinical nicotine study NIC-H22-1. Current cigarette smokers are participating in the 36-person human pharmacokinetic randomized, double blinded, cross-over study, wherein each person will visit the laboratory to be dosed three times over the coming weeks. Only one oral nicotine pouch (DehydraTECH-nicotine, On! brand manufactured by Altria, or Zyn brand manufactured by Swedish Match) will be administered and evaluated during each visit. The primary objectives are to determine the quantity of nicotine in blood at various time points and collection of vital-sign data of temperature, blood pressure, heart rate and respiratory rate. In addition, subjective evaluations related to throat burn, user experience, gastrointestinal experience and more will be conducted.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LEXX) Stock Research Links
Scroll down for more posts ▼